Floatz logo

DHA

Obesity

Bambino Gesù Hospital and Research InstituteSmall moleculePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB

View all 50 →

Same molecule, other indications

DHA is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
64 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
64 / 100
View asset →
Obesity, AbdominalDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →